GLP-1 Drug Discontinuation Increases Cardiovascular Risk
Analysis based on 9 articles · First reported Mar 18, 2026 · Last updated Mar 24, 2026
The study's findings suggest a negative market impact for GLP-1 drug manufacturers like Novo Nordisk and Eli Lilly and Company, as the necessity for continuous, long-term use highlights challenges with patient adherence due to cost and side effects. This could lead to increased pressure on companies to address affordability and improve patient support to maintain market share and sustained revenue from these popular medications.
A new study by Washington University in St. Louis, led by Ziyad Al-Aly, revealed that discontinuing GLP-1 drugs like Novo Nordisk===Semaglutide, Novo Nordisk===Semaglutide, Eli Lilly and Company===Tirzepatide, and Eli Lilly and Company===Tirzepatide, even for short periods, significantly increases the risk of heart attack, stroke, and death. The research, published in BMJ Medicine and based on data from over 333,000 U.S. veterans with type 2 diabetes, found that cardiovascular benefits gained from continuous use are quickly lost upon cessation. Interruptions as short as six months reduced benefits, and discontinuations of one or two years led to a 14% to 22% increased risk of major cardiovascular events. The study emphasizes that GLP-1s are chronic treatments, and metabolic reversals occur when patients stop, underscoring the importance of continuous adherence for sustained heart protection. Factors like cost, side effects, and shortages contribute to discontinuation, prompting calls for healthcare systems to develop strategies to support long-term patient adherence.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard